The latest market report published by Acute Market Reports “Global Respiratory Tract Infection Treatment Market Growth, Future Prospects, Competitive Analysis and Pipeline Analysis, 2023 - 2030,” the global respiratory tract infection treatment market is expected to reach US$ 78,544.0 Mn by 2030 expanding at a CAGR of 6.2 % from 2023 to 2030.
Browse the full report Global Respiratory Tract Infection Treatment Market at https://www.acutemarketreports.com/report/respiratory-tract-infection-treatment-market
Market Insights
Microbes gain entry to the respiratory tract by inhalation of droplets and invade the mucosa. Causative agents of lower respiratory infections are viral or bacterial. Symptoms include cough, fever, chest pain, tachypnea and sputum production. Patients with pneumonia may also exhibit non-respiratory symptoms such as confusion, headache, myalgia, abdominal pain, nausea, vomiting and diarrhea. In the base year 2021, the upper respiratory tract infection are leading the disease segment due to factors such as constant climate change and air pollution, gross negligence when it comes to personal hygiene like sneezing, coughing (uncovered face) and touching inanimate objects with contaminated hands. Lower respiratory tract infection are anticipated to register faster growth in the disease segment throughout the forecast period 2023-2030, due to factors like rising number of air particulate matter, which causes respiratory tract irritation and infection and on the basis of transmission it might be hospital-acquired, ventilator acquired, and community acquired. In 2021, NSAIDs holds the largest market in the drug class segment due to factors such as low cost and easy availability as OTC products, technological advancement in the drug formulation e.g. ketorolac nasal spray to overcome NSAIDs adverse events. The antibiotics will be the fastest growing market in the drug treatment segment throughout the forecast period 2023-2030, due to factors such as improved pharmacokinetics to specifically target respiratory tract infection for e.g. Colistin inhalers. The respiratory tract infection treatment is technologically driven and includes major players such as Abbott Laboratories, AstraZeneca, Boehringer Ingelheim GmbH, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd. are a few market leaders in respiratory tract infection treatment and compete to augment their foothold in the market.
Key Market Movements:
- Higher public awareness and preference to maintain personal hygiene
- Rising number of respiratory complications in children and geriatric population
- Regulatory approval for drugs used in the treatment for respiratory tract infection
- Constantly changing climate and rise in air particulate matter due to industrial and automobile emission
